Skip to content
ARTHEx biotech
  • About us
  • Our products
  • Pipeline
    • Publications
  • Team/Investors
  • Contact/Events
  • News

J.P. MORGAN

July 24, 2020February 26, 2019 by Abel Rodriguez

January 2019:

ARTHEx S.L. participation at the 37th Annual J.P. Morgan Healthcare Conference, celebrated from January 7 to 10 2019 in San Francisco, California.

Participation at the 37th Annual J. P. Morgan

Share this post
  • Share on Facebook
  • Tweet on Twitter
Categories News
Post navigation
BIO International Convention
International Myotonic Dystrophy Consortium

Arthex on Twitter

AvatarARTHEx biotech@Arthexbiotech·

Seguimos trabajando para que el AntagomiR-23b se convierta en realidad, y este magnífico trabajo del grupo de @ramon_azcon informa de que vamos por bien camino!

Hacia un tratamiento para la distrofia miotónica: primer modelo 3D con células de pacientes https://ibecbarcelona.eu/es/hacia-un-tratamiento-para-la-distrofia-miotonica-primer-modelo-3d-con-celulas-de-pacientes/

AvatarARTHEx biotech@Arthexbiotech·

Nuestro CEO, Dra. Beatriz Llamusí, hablará este Miercoles en la jornada online "Presente y futuro del desarrollo de tratamientos para la Distrofia Miotónica Tipo 1!

12 de mayo a las 17:00h CEST
#MyotonicDystrophy

AvatarARTHEx biotech@Arthexbiotech·

🏅Arthex Biotech es uno de los orgullosos finalistas del premio emprendedor XXI #EmprendedorXXI de la Comunidad Valenciana. Te invitamos el próximo jueves 29 de Abril #DayOneInnovationSummitCiudadXXI donde conoceremos a la startup ganadora.

👇No te lo pierdas!!

Retweet on TwitterARTHEx biotech Retweeted
AvatarFederación ASEM@Federacion_ASEM·

¡No te pierdas la jornada online "Presente y futuro del desarrollo de tratamientos para la Distrofia Miotónica Tipo 1! 💊🔬
📅 12 de mayo a las 17:00h CEST.
Con:
🎙Dr. Ruben Artero
🎙Dr. Arturo López
🎙Dra. Beatriz Llamusí
Inscripciones aquí 👉 https://www.asem-esp.org/noticias/jornada-online-desarrollo-de-tratamientos-para-la-distrofia-miotonica-tipo-1/
#DM1

2
Load More...

News

  • We are delighted to announce a new addition to our growing team, Sheila Soriano May 25, 2021
  • Different awards and grants recognize ARTHEx’s efforts to start up an innovative treatment for DM1 November 28, 2020
  • Eric Marcusson joins ARTHEx’s  Scientific Advisory Board November 2, 2020
  • Dr Nicholas Jonhson, new Chief Medical Advisor August 28, 2020
  • Arthex secures €4.25M from Invivo Ventures and Advent France Biotechnology July 24, 2020
Logo blanco
Drug discovery in neuromuscular diseases
ARTHEX BIOTECH. S.L
C/ Catedrático Agustín Escardino 9 – 46980 Paterna, Valencia (Spain)
Telephone: +34 625 016 629 – E-mail:  info@arthexbiotech.com
Linkedin   Facebook   Twitter
logo innvierte
logo Ministerio de Ciencia e Innovación
eit
Logo de la Generalitat
IVACE
Logotipo neotec
© 2021 ARTHEx biotech • Built with GeneratePress
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Read MoreACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.

SAVE & ACCEPT